SARS-CoV-2 - Clevudine - Therapeutic Candidates

SARS-CoV-2 - Clevudine - Therapeutic Candidates


Clevudine, marketed as Levovir and Revovir, is a synthetic pyrimidine analogue. It is an antiviral drug used in the treatment of hepatitis B. In cells, clevudine is phosphorylated into its active metabolites, clevudine monophosphate and clevudine triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, causing DNA chain termination and inhibiting the function of the hepatitis B virus (HBV) DNA polymerase (reverse transcriptase). Clevudine has a long half-life and exhibits a significant reduction in covalently closed circular DNA (cDNA), so that the patient is less likely to relapse after cessation of treatment.
A study is currently underway to evaluate the safety and efficacy of clevudine in patients with a moderate form of COVID-19 caused by CoV-2 SARS. In this Phase 2 study, clevudine is combined with hydroxychloroquine.

Cat#
Description
Size
Price Excl. VAT
HY-13859-1mL
 10mM/1mL 
HY-13859-10mg
 10mg 
HY-13859-50mg
 50mg 
M5526-10mg
 10 mg 
M5526-50mg
 50 mg 
S6446-2mg
 2mg 
S6446-5mg
 5mg 
295620-1g
 1g 
295620-2g
 2g 
295620-500mg
 500mg 
B1912-10mg
 10 mg 
B1912-50mg
 50 mg 
S6446-10mg
 10mg 
S6446-25mg
 25mg 
295620-100mg
 100mg 
S6446-50mg
 50mg 
295620-250mg
 250mg 
C574150-100mg
 100mg 
C574150-10mg
 10mg 
C574150-1g
 1g 
C574150-250mg
 250mg 
C574150-500mg
 500mg 
C574150-50mg
 50mg